Iovance Biotherapeutics
IOVA
$4.37
+2.10%
Iovance Biotherapeutics is a clinical-stage biopharmaceutical company pioneering autologous tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers, with its lead candidate targeting advanced melanoma and other indications. As a first-mover in TIL therapy for solid tumors, Iovance holds a distinct competitive position in the immuno-oncology space, aiming to become the first approved autologous T-cell therapy for a solid tumor. The current investor narrative centers on the company's transition from a clinical-stage to a commercial-stage entity, with recent FDA approval and launch of its first therapy driving attention, while debates around commercial execution, pipeline expansion, and path to profitability fuel both optimism and skepticism.…
IOVA
Iovance Biotherapeutics
$4.37
Related headlines
IOVA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Iovance Biotherapeutics's 12-month outlook, with a consensus price target around $5.68 and implied upside of +30.0% versus the current price.
Average Target
$5.68
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$4 - $6
Analyst target range
Iovance is covered by 3 analysts, with a consensus recommendation leaning bullish. The average target price is not directly provided, but the estimated EPS average of $0.43 and revenue average of $1.23 billion imply a forward PE of approximately 10x (based on current price of $4.31), suggesting significant upside if profitability is achieved. The high EPS estimate of $0.46 and low of $0.40 indicate a tight range, reflecting relatively high conviction among analysts. The implied upside from current price to the average target is not calculable without explicit target prices, but the positive EPS estimates suggest analysts expect the company to turn profitable within the next fiscal year. The target range (low to high) for EPS is narrow ($0.40-$0.46), signaling strong agreement on near-term earnings potential. However, the limited analyst coverage (3 analysts) means the stock may have less institutional attention, leading to higher volatility and less efficient price discovery. The recent news highlights a 165% upside target from one source, but this is speculative and not part of the consensus analyst data. Overall, the analyst sentiment is cautiously optimistic, with expectations of a turnaround to profitability driven by commercial launch of TIL therapy.
Drowning in data?
Find the real signal!
IOVA Technical Analysis
Iovance's stock is in a strong uptrend over the past year, with a 1-year price change of +146.3%, significantly outperforming the S&P 500's +19.1% gain. The current price of $4.31 sits at 63.5% of its 52-week range ($1.68-$5.63), indicating the stock is in the upper half of its range but not yet at overbought extremes, suggesting room for further upside if momentum persists. The 52-week low of $1.68 and high of $5.63 provide clear boundaries for the trend. Short-term momentum is accelerating, with a 1-month price change of +5.1% and a 3-month change of +25.7%, both outpacing the S&P 500's respective -1.25% and +13.6% returns. The relative strength index (RSI) is not provided, but the consistent positive momentum over 3 and 6 months (+71.0%) suggests strong buying interest, though the 1-month gain is modest relative to the longer-term trend, indicating a potential consolidation phase. Key support lies near the 52-week low of $1.68, while resistance is at the 52-week high of $5.63. A breakout above $5.63 would signal a continuation of the uptrend and potentially target new highs, while a breakdown below $1.68 would indicate a reversal. The stock's beta of 0.69 implies it is 31% less volatile than the S&P 500, making it a relatively lower-risk biotech holding, though individual stock risk remains high due to binary pipeline events.
Beta
0.69
0.69x market volatility
Max Drawdown
-54.4%
Largest decline past year
52-Week Range
$2-$6
Price range past year
Annual Return
+119.6%
Cumulative gain past year
| Period | IOVA Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | +2.0% |
| 3m | +18.1% | +10.6% |
| 6m | +78.4% | +8.3% |
| 1y | +119.6% | +20.4% |
| ytd | +73.4% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IOVA Fundamental Analysis
Iovance's revenue trajectory is nascent, with the most recent quarterly revenue not provided, but the company is generating initial sales from its approved TIL therapy. The PS ratio of 3.70x suggests the market is pricing in significant future revenue growth, though the company remains pre-revenue on a large scale. The estimated revenue for the next fiscal year is $1.23 billion, implying a dramatic ramp from near-zero levels, which underscores the high-growth expectations but also execution risk. Gross margin is exceptionally high at 97.2%, typical for cell therapies, but operating margin is deeply negative at -153.1%, reflecting heavy R&D and SG&A spending. Net income is negative, with an EPS of -$0.40, and net margin of -148.4%, indicating the company is still investing heavily in commercialization and pipeline development. The trajectory toward profitability is uncertain, as losses are expected to narrow with revenue growth, but the timeline depends on commercial adoption and cost control. The balance sheet shows a current ratio of 3.20x, indicating strong short-term liquidity, and a debt-to-equity ratio of just 0.07, suggesting minimal leverage. However, free cash flow is negative (PCF ratio of -3.23x), meaning the company is burning cash to fund operations. ROE is -56.0%, reflecting significant losses relative to equity, but the low debt levels provide financial flexibility. The company may need to raise additional capital to fund operations until it achieves positive cash flow, which could dilute shareholders.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IOVA Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 3.70x, while forward PS (based on estimated revenue of $1.23B and market cap of $975.6M) is approximately 0.79x, implying the market expects a massive revenue surge. The wide gap between trailing and forward PS reflects the transition from pre-revenue to commercial stage. Compared to the biotechnology industry average PS ratio of approximately 5-10x for early-stage companies, Iovance's trailing PS of 3.70x appears reasonable, but the forward PS of 0.79x suggests deep value if revenue targets are met. However, the industry average for profitable biotechs is lower, so the premium/discount is nuanced. Historically, Iovance's PS ratio has fluctuated widely; the current trailing PS of 3.70x is near the lower end of its historical range (which has exceeded 20x in the past), indicating the stock is relatively cheap compared to its own history. This could reflect market skepticism about revenue sustainability or a value opportunity if commercial execution succeeds.
PE
-2.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.4x
Enterprise Value Multiple
